How did polivy's trials measure treatment effectiveness?

Question

Accepted Answer

Polatuzumab vedotin (Polivy™) was evaluated in a series of phase‑I/II and phase‑III trials that used a combination of imaging‑based response criteria and time‑to‑event endpoints to gauge how well the drug worked. The key measures were:

Trial / Setting	Primary/Key Endpoints	How they were assessed
Phase‑I/II “P‑01” (first‑in‑human)	1. Overall Response Rate (ORR) – the percentage of patients who had a complete response (CR) or partial response (PR) after a defined number of cycles. 2. Duration of Response (DOR) – the time from the first documented response to disease progression or death.	• PET‑CT scans (or CT alone) at baseline and after every 2–4 cycles, scored using the International Working Group (IWG) 2007 criteria (later updated to the Lugano 2014/2017 guidelines). • Response was independently reviewed by a central review committee.
Phase‑III “POLARIX” (first‑line DLBCL)	1. Overall Response Rate (ORR) at 6 months. 2. Complete Response (CR) rate. 3. Progression‑Free Survival (PFS). 4. Overall Survival (OS). 5. Event‑free survival (for a subset of patients).	• Imaging (CT ± PET‑CT) every 3 cycles, using Lugano criteria. • Survival endpoints were tracked via scheduled visits and electronic health records. • Independent data monitoring committee (IDMC) performed blinded review of imaging.
Phase‑III “POLARIS” (relapsed/refractory DLBCL)	1. ORR (primary). 2. CR rate. 3. PFS. 4. OS. 5. Disease‑free survival for those achieving CR.	• Same imaging protocol (CT ± PET‑CT) at baseline, post‑cycle 2, 4, and then every 3 cycles. • Central review and IWG/Lugano scoring. • Time‑to‑event data collected from routine follow‑up and electronic records.

How the endpoints were defined and measured

Imaging (RECIST/Lugano)
- RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) was used for solid‑tissue measurements, but because DLBCL is a lymphoma, the Lugano 2014/2017 update (a refinement of IWG) was the standard.
- CR = disappearance of all target lesions and no evidence of disease on PET‑CT (if PET‑CT used).
- PR = at least a 30 % reduction in the sum of diameters of target lesions and no new lesions.
- Stable disease (SD) or progression (PD) were also recorded; PFS was defined as the time from randomization to the first PD or death.
Time‑to‑Event Endpoints (PFS, OS, DOR)
- Progression‑Free Survival (PFS): time from the start of therapy to either radiologic disease progression or death from any cause.
- Overall Survival (OS): time from randomization to death from any cause.
- Duration of Response (DOR): for patients who achieved CR or PR, the interval from the first documented response to the next documented progression or death.
- These were evaluated by the study’s independent data monitoring committee and confirmed by regular follow‑up visits.
Safety and Quality‑of‑Life (QoL) Sub‑analyses
- While not the primary “effectiveness” endpoints, QoL questionnaires (e.g., EORTC QLQ‑C30) and safety tables helped contextualize the benefit‑risk profile.
Statistical Considerations
- Power calculations were based on detecting a clinically meaningful difference in ORR or PFS (often a 10–15 % absolute improvement).
- Kaplan–Meier survival curves were plotted, and hazard ratios (HRs) with 95 % confidence intervals were derived using Cox regression models.

Bottom line

Polivy’s trials measured effectiveness through a multi‑tiered approach:

Early response (ORR/CR) using standardized imaging criteria.
Durability via DOR.
Survival impact with PFS and OS.
Independent review to avoid bias.

These metrics together paint a comprehensive picture of whether the drug actually improves patient outcomes compared to standard regimens.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

How did polivy's trials measure treatment effectiveness?

How the endpoints were defined and measured

Bottom line